Gapping down
In reaction to disappointing earnings/guidance:
- IMMR -19.7%, NTNX -19.2%, BBG -9.4%, CGG -7%, WING -6.8%, FSTR -6.6%
- AOBC -5.1%, RGLS -4.5%, AMRS -4.5%,
- COST -4.3%, (Costco also confirmed plans for membership fee increase ), ADSK -1.7%
Other news:
- SCYX -22.6% (delays the initiation of any new clinical studies with the IV formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data of the IV formulation of SCY-078)
- KPTI -15.1% (announced the results of a planned interim analysis of the Phase 2 SOPRA study evaluating single agent selinexor in relapsed/refractory acute myeloid leukemia; study will not reach statistically significant improvement in primary endpoint of overall survival in patients who are unfit for chemotherapy and/or transplantation )
- HMSY -10.5% ( files to delay its 10-K; is continuing to evaluate whether this issue affects its consolidated financial results, primarily focusing on prior periods in which revenue relating to the CMS business was recorded)
- ZSAN -9.7% ( files for $46 mln common stock offering)
- BLDR -1.5% (commences a secondary offering of 10,000,000 shares of its common stock to be sold by JLL Building Holdings)
Analyst comments:
- KITE -1.5% (downgraded to Hold at Stifel)
- CIEN -1.5% (downgraded to Neurtral at BofA/Merrill)